[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemato-oncologic-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemato-oncologic-patients":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100623433","predictive-score-in-patients-with-hematological-malignancies-colonized-by-multidrug-resistant-enterobacteriaceae-100623433",false,"NCT07396571","Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae","Development of a Predictive Infection Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae","SCREEN-IN","Inclusion criteria\n\n* Patients admitted to Hematology departments with hematological diseases, including: myelodysplastic syndrome, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia, chronic myeloproliferative leukemias, lymphomas, or other hematological disorders.\n* Patients scheduled to receive treatment for their underlying hematological disease, including myeloablative\u002Fcytotoxic chemotherapy, conditioning chemotherapy for hematopoietic stem cell transplantation (autologous, allogeneic, or other types), lymphodepleting chemotherapy for CAR-T cell therapy, and\u002For other treatments expected to induce neutropenia.\n* Patients expected to develop neutropenia (neutrophil count \\\u003C 0.5 \\\\times 10\\^9\u002FL, or \\\u003C 1.0 \\\\times 10\\^9\u002FL when predicted to fall below 0.5 \\\\times 10\\^9\u002FL within the next 48 hours) in the coming days.\n* Those who have signed the informed consent form.\n* Participation in another study is permitted, provided it is observational and does not influence the potential colonization status.\n\nExclusion criteria\n\n* Psychiatric disorder or inability to understand or follow the protocol instructions.\n* Terminally ill patients or those with an estimated life expectancy of less than 30 days.\n* Previous enrollment in the study.\n* Known prior colonization by ESBL-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE).\n* Physician's discretion: The patient's attending physician prefers not to include the patient in the study.","ALL","18 Years",{"count":20,"type":21},535,"ESTIMATED","OBSERVATIONAL","The goals of this observational study are to identify risk factors for ESBL-producing Enterobacterales and carbapenemase-producing Enterobacterales (CPE) colonization in oncohematological patients with severe neutropenia, and to develop and validate a predictive model of infection caused by ESBL-producing Enterobacterales and CPE in patients previously colonized by the same bacteria.\n\nThe main questions the study aims to answer are:\n\n* What are the risk factors for ESBL-producing Enterobacterales and CPE colonization in patients with severe neutropenia?\n* Can a predictive model be developed to accurately predict infections in the colonized patients?\n\nStudy Design \\& Participants: Participants will be screened after receiving neutropenia-inducing treatment (e.g., chemotherapy, chimeric antigen receptor T-cell (CAR-T) therapy, or others). A baseline rectal swab will be collected to assess initial colonization status, followed by weekly swabs throughout the duration of neutropenia. Patients will be followed for 90 days from initial screening, during which the study team will record any infections, with an additional 30-day follow-up period. All hospitalization data will be recorded.",[25,26,27,28,29],"Hemato-oncologic Patients","Colonization","Neutropenia","Enterobacteria Non Susceptible to Carbapenem Carrier","ESBL-producing Enterobacteriaceae Infections","NOT_YET_RECRUITING","2026-02-27",{"date":33,"type":34},"2026-03-02","ACTUAL",{"date":36,"type":21},"2026-02",{"date":38,"type":21},"2028-12",{"name":40,"class":41},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","OTHER",15,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":5},"100620837","phase-2-g-csf-combined-with-il-11-on-hematopoietic-reconstitution-after-autologous-hematopoietic-stem-cell-transplantation-100620837","NCT07362810","G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation","The Impact of G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Adults (≥18 years) with newly diagnosed multiple myeloma or lymphoma\n* Suitable candidates for autologous hematopoietic stem cell transplantation (auto-HSCT)\n* Zubrod (ECOG) performance status \\\u003C 4\n* Left ventricular ejection fraction (LVEF) \\> 40%\n* No uncontrolled arrhythmia or unstable cardiac disease\n* Corrected QT interval (QTc) \\\u003C 470 ms\n* No symptomatic pulmonary disease, with acceptable pulmonary function tests\n* Serum alanine aminotransferase (ALT) \\\u003C 4 × upper limit of normal (ULN)\n* Total bilirubin \\\u003C 2 × upper limit of normal (ULN)\n\nExclusion Criteria:\n\n* Intolerance to auto-HSCT\n* Prior exposure to other stem cell mobilizing agents\n* Pregnancy or lactation\n* Psychiatric disorders precluding participation\n* Positive serology for HIV (HIV-1\u002F2), hepatitis B, or hepatitis C","70 Years",{"count":52,"type":21},224,"INTERVENTIONAL",[55],"PHASE2","Autologous hematopoietic stem cell transplantation(auto-HSCT) plays an important role in treating hematologic malignancies. Mobilization and collection of peripheral blood stem\u002Fprogenitor cells is the key to successful autologous hematopoietic stem cell transplantation. Currently mobilization regimens are not enough in increasing the yield of megakaryocytic or erythroid stem\u002Fprogenitor cells, resulting in a delay of hematopoietic reconstitution of platelets and erythrocytes. IL-11 and G-CSF have a synergistic role in mobilizing peripheral blood stem cells towards megakaryocytic or erythroid stem\u002Fprogenitor cells in a preclinical study. Furthermore, a single-center, small cohort, prospective clinical study that has been completed in China(ChiCTR2500100054), which showed that after five days of mobilization, the combination of G-CSF and IL-11 significantly increased the number and proportion of functional megakaryocytic\u002Ferythroid progenitor cells in the peripheral blood mononuclear cells of patients, and also significantly shortened the time for platelet engraftment after transplantation, and also reduced the demand for red blood cell and platelet transfusions compared to G-CSF alone. A multi-center, prospective random clinical study is essential to compare the efficacy and safety of novel mobilization regimen with IL-11 plus G-CSF to G-CSF alone.",[58,59,25],"Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)","Hematopoetic Stem Cell Transplantation",[61,62,63],"IL-11","mobilization","hematopoetic stem cell transplantation","RECRUITING","2026-01-22",{"date":67,"type":34},"2026-01-23",{"date":69,"type":21},"2026-01-01",{"date":71,"type":21},"2026-12-30",{"name":73,"class":41},"Fudan University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":53,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100588278","log-i---impact-study-of-log-after-software-on-long-term-monitoring-of-former-patients-log-i---log-impact-study-100588278","NCT06939322","LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study)","LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) \u002F Etude d'Impact du Logiciel LOG-AFTER Sur le Suivi à Long Terme Des Anciens Patients (LOG-I - LOG-Impact Study)","LOG-I","Inclusion Criteria:\n\n* Previously treated for cancer or malignant hematological pathology before the age of 25\n* Without residual disease or with a stable disease without treatment for 5 years or more\n* Owning a computer, smartphone or equivalent I-Pad\u002Ftablet with internet access\n* Having signed the consent (or their parents if the patient is a minor, or a third party if necessary)\n* Having 3 or more recommended screenings in their survivorship care plan\n* No access created to LOG-AFTER before the study or having never connected after opening their account if opening an account dating back 24 months or more at the time of inclusion\n\nExclusion Criteria:\n\n* Patient who has relapsed or developed a second cancer with a post-treatment delay \\\u003C 5 years\n* Patient not covered by a health insurance\n* Patient subject to a legal protection measure, patient deprived of liberty by judicial or administrative decision, patient subject to psychiatric care under duress","15 Years",{"count":84,"type":21},320,[86],"NA","Childhood cancer survivors represent a high-risk population that requires risk-based follow-up. Follow-up recommendations have been harmonized. Education and information practices regarding follow-up recommendations should be personalized, to ensure understanding by all survivors, including those with neurocognitive disorders. Individualized follow-up is necessary to detect complications that may increase morbidity and decrease quality of life, or even increase the risk of early mortality.\n\nIn France, the LOG-AFTER software was developed in 2017 by university hospital of Angers and Epiconcept (approved health data host). The main differences with the European procedure concern radiotherapy information, the link with the General practitioner (GP), and the possible addition of information and\u002For access to therapeutic education in a video format. Indeed, there is the possibility of creating an GP account allowing to receive notifications concerning the follow-up of his patient to be scheduled, to have access to his file summary and his personalized follow-up plan, various information and blank prescription models. LOG-I is a study of the impact of the LOG-AFTER software for the \"patient\u002FGP\" couple on adherence to follow-up recommendations. LOG-I is interested in all former patients with at least 3 recommendations in their personalized follow-up plan, taking into account the specific population of patients cured of a brain tumor.",[89,90,25],"Pediatric Cancer","Cancer Survivor",[92,93,94,95,96,97],"pediatry","oncology","hematology","radiotherapy","survivorship","preventive care","2025-06-27",{"date":100,"type":34},"2025-07-02",{"date":102,"type":34},"2025-06-06",{"date":104,"type":21},"2030-06-06",{"name":106,"class":107},"University Hospital, Angers","OTHER_GOV",1,"Hemato-Oncologic Patients"]